BioMarin Q3 2023: revenue $581M (+15% YoY), VOXZOGO $123M (+155%), cuts ROCTAVIAN guidance

BIOMARIN PHARMACEUTICAL INC

2023-Q3 EPS reported $0.77 revenue$1,773,019,000

Q3 total revenue $581.3M (+15% YoY), GAAP net income $40.4M vs loss $6.7M, GAAP diluted EPS $0.21 vs ($0.04).
VOXZOGO revenue $123.1M (+155% YoY); full-year guidance raised to $435-455M from $400-440M.
ROCTAVIAN revenue $0.8M; full-year guidance slashed to <$10M from $50-150M due to pricing delays.
Full-year 2023 total revenue guidance narrowed to $2.39-2.47B; Non-GAAP diluted EPS guided $1.90-2.05.
Management expects 2024 revenue to approach $3B; VOXZOGO age expansions in US and EU; hypochondroplasia trial to start.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIOMARIN PHARMACEUTICAL INC updated its full-year 2023 guidance (reaffirmed).

Period: full-year 2023
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

"Results in the quarter drove double-digit revenue growth year-over-year and supports BioMarin’s full-year 2023 revenue and profitability objectives, set at the beginning of the year,"

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIOMARIN PHARMACEUTICAL INC reported third quarter ended September 30, 2023 results: revenue $581.3 million, net income $40.4 million, EPS $0.21.

Period: third quarter ended September 30, 2023
Revenue: $581.3 million
Net income: $40.4 million
EPS: $0.21
Result: reported results

Exact text from the filing

facilitate patient access, setting the stage for meaningful uptake of ROCTAVIAN in 2024.” Third Quarter Financial Highlights: • Total Revenues for the third quarter of 2023 were $581.3 million, an increase of 15% compared to the same period in 2022. The increase in Total Revenues was primarily attributed to the following: ◦ higher VOXZOGO sales volume due to new

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

BIOMARIN PHARMACEUTICAL INC filing history →

Source: SEC EDGAR

accession 0001048477-23-000041

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.